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Abstract Albumin nanoparticles are already used for the
treatment of the cancer. In our current work, it is presented
the technique for the preparation of small-size 1- to 5-mi-
cron particles coated with the allopurinol. We propose that
this combination of the compounds might be useful for the
ischemic stroke treatment as the agent preventing forma-
tion of the brain edema, reactive oxygen species, and ini-
tiation of cells regeneration. Glutaraldehyde was used for
the polymerization of albumin. Determination of the par-
ticle size was performed by the light as well as phase
contrast microscopies and analyzed by Pixcavator 6.0 and
Image Tool programs. Modification and establishment of
iodine-based method served as the base for quantification
of bound with the particles and free allopurinol. As a
consequence of the experiments, the best formulation of
glutaraldehyde ratio and albumin quantity as well as con-
ditions for the formation of the smallest sized spheroid-
shaped particles were found for the further in vivo
application.







In blood plasma, albumin is one of the multifunctional
proteins which is found abundantly, 35–50 mg/ml [1].
Human serum albumin has a molecular weight equal to
66.348 kDa [2, 3]. Human albumin consists of three
domains: I, II, and III. Each domain has A and B subdo-
mains. Crystallographic analysis of HSA has established
that this protein contains 67 % a-helical and no b-sheet [3].
The remaining structure, 33 %, consisting of the polypep-
tidic loop part, which makes the link between A and B
subdomains, is as long as 20 amino acids. The helixes are
locked together by 17 disulfide bonds, which, as believed,
guarantee a thermal stability of the protein [4]. Fatty acid
binding to HSA induces large-scale changes in the protein
conformation, rotating domains I and III relative to domain
II [4–6].
Based on Sudlow’s early work, it was shown that drugs
bind to two primary sites in subdomains, namely, IIA and
IIIA [2, 7]. These sites are similar and contain six helixes
[4]. However, recent work showed that the steroid antibi-
otic, fusidic acid binds specifically to subdomain IB [8].
The human albumin gene is located on the long arm of
chromosome 4 at position q13.3 [3].
Albumin might be synthesized in the liver and its total
amount is 13.9 mg/day [1]. The main function of the
albumin is to support osmotic pressure [1]. This protein
binds to various endogenous compounds including long-
chain fatty acids, steroids, and L-tryptophan [9]. Albumin
can also serve as a transporting agent for the delivery of
copper, zinc, and calcium ions [1]. This plasma protein is
able to carry medicines such as warfarin, ibuprofen,
chlorpromazine, and naproxen. Binding of the compounds
to albumin changes their targeting effects as well as the
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circulation time [10]. Consequently, albumin might serve
as a carrier not only for the medicines but also for the
toxins, for instance bilirubin [1].
Compared to synthetic polymers, proteins possess several
advantages: They might be degraded into the peptides by
naturally occurring enzymes; in comparison with the
chemically synthesized nanomolecules, they may accumu-
late in the body and result in toxic degradation products [11].
Electrostatic interactions, hydrophobic attractions, and
covalent bindings are the mechanisms allowing attaching the
drug with the carrier. Also, these nanoparticles are able to be
modified and present the attached molecules to the surface
of the targeted cells [11]. It was demonstrated that uptake of
albumin–paclitaxel nanoparticles is presumably mediated by
the gp60 transcytosis pathway and subsequent binding to
secreted protein, acidic and rich in cysteine (SPARC) in the
tumor extracellular matrix [12].
In our current work, we are presenting the method for
the formation of the albumin particles, which are coated
with the allopurinol solution.
Allopurinol is one of the classical inhibitors of Xanthine
Oxidase (XO), and one of the last enzymes of purines
catabolism responsible for the formation of uric acid. It has
a wide utility for the treatment of podagra. The by-products
of XO activity are the reactive oxygen species (ROS).
Recently, allopurinol was used in the clinical trial with
involvement of the stroke patients. The published results of
these trials are contradictive [13, 14].
We think that albumin nanoparticles carrying allopuri-
nol will not possess negative side effects, including trig-
gering liver necrosis. Also, the frequency of the treatment
after utility of the allopurinol-coated particles in compar-
ison with the free allopurinol will be less, which will
improve the efficiency of this medicine. Allopurinol is
metabolized by the liver with the t1/2 equal to 1–2 h.
Binding with the albumin particles will prolong circulation
time of this medicine and, consequently, will reduce the
metabolic rate and prolong time of its gradual influence
without necessity of second dosage uptake.
Materials and methods
Preparation of the nanoparticles
Different concentrations of serum albumin (Sigma) were
dissolved in 1 ml of water. Numerous concentrations of
glutaraldehyde and 14 ml of ethyl alcohol were added
(GA; 25 %, Medisar, Armenia). We have used 20, 200, and
500 mg of the albumin for the formation of the particles as
well as 50, 500, and 2000 ll of glutaraldehyde to be able to
delineate the best composition for the formation of the
small, spheroid-type particles. This mixture was incubated
for 24 h. Also, these reactions were carried out in water vs
ethanol solution. The mixture was centrifugated at 8000
RPM for 15 min. The precipitate was dissolved in 3 ml of
water, and the particles were washed from the remaining
parts of the glutaraldehyde. The remaining part of the
precipitate was dissolved in 400 ll of 1 9 PBS [15–19].
For better visualization, when the formation of particles
was completed, they were mixed with 2 ml of 2 % solution
of Evans Blue (Sigma).
Microscopy
The work was performed with the utility of light microscopy
as well as phase contrast lenses system with 1009 of objec-
tive magnification (Binocular Biological Microscope, Model
BM-180/I/SP, Germany). The number of the particles as well
as the size of the formed albumin polymers was assessed with
the Pixcavator 6.0 as well as Image Tool programs.
Determination of the bound allopurinol
with the particles
The method is based on the ability of the iodine ethylene
solution (3 %) to oxidize allopurinol and to form the pre-
cipitate. The spectrophotometric method was developed, and
absorption was measured at 480 nm. Particle suspension
(50 ll) was dissolved in 910 ll of PBS (19), and 40 ll of
iodine solution was added (20 ll of 3 % iodine was dis-
solved in 10 ml PBS buffer). To measure the absorption,
PerkinElmer Junior spectrophotometer was used [20].
Iodometric oxidation reaction for calculation
of allopurinol
Purine derivatives such as the structures containing azo are
able to form hardly dissolved complex compounds, which
might be visualized by spectrophotometric techniques. The
reaction was performed in acidic environment [21]. Twenty
microliters of 3 % ethanol iodine solution was dissolved in
10 ml of buffer. As detecting agent, it was used 40 ll of
above mentioned iodine solution. The quantity of the
allopurinol/1 ll was calculated after normalization with the
particles containing precipitate or supernatants control
solutions based on the following equation, where X the
concentration and Y is the absorption.
X ¼ ðY=1:657Þ=50
Results
1. Determination of the albumin particles size utilizing
Image Tool program.
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The experiments were performed with three groups of
particles. The total quantity of the protein, which was
polymerizing, was equal to 200 mg. The analysis of
the particles’ size revealed that the group with the
addition of 50 ll GA had a surface area equal to
62.946 ± 2.697 l, as well as 162.775 ± 7.055 l.
Addition of 200 ll of the GA provokes particles for-
mation with surface area equal to 78.004 ± 7.642 and
221.992 ± 39.859. Addition of 500 ll of GA results
formation of the particles with the surface area equal to
62.449 ± 2.431 and 212.852 ± 15.482 l (Fig. 1).
2. Determination of the formed particles number in the
microscope field.
By adding of 2000 ll of GA, the highest number of
particles was formed and was equal to 23.3 ± 7.93. In
50- and 200-ll GA groups, the number of the particles
in the statistically significant way was different from
the previously mentioned group and was equal to
5.7 ± 1.136 and 6.6 ± 1.949 (Fig. 1).
3. Formation of the particles in the presence of different
concentration of the protein and determination of the
number of formed particles (Fig. 2).
The number of the formed particles was evaluated after
mild changes of the conditions of the experiment. After
24-h incubation, the mixture was centrifugated for
15 min, RPM = 8000. The precipitate was
resuspended in water, and the samples were evaluated
with the utility of light as well as phase contrast
microscopy. The maximal number of the particles was
observed in the samples with the addition of 20 mg of
the protein 699.00 ± 35.87; in the samples with the
addition of 200 mg of the albumin, the number was
equal to 468.00 ± 51.87, whereas addition of 500 mg
resulted in the consequential formation of
288.76 ± 17.83 particles. It is quite interesting to
mention that the shape of the particles was spheroid
and did not look like a flake as it is shown in the Fig. 3.
To have better visualization, the particles were stained
with Evans Blue.
4. Formation of the particles in the presence of different
concentration of the protein and determination of size
of formed particles.
The size of the particles was gradually increasing with
the increase in the concentration of the protein. In
20-mg samples the number was equal to
0.0155 ± 0.001, in 200 mg—0.036 ± 0.003, and the
largest particles were formed after addition of 500 mg
of protein (0.056 ± 0.003). The results of comparison
of the groups were statistically significant.
We also compared the shape of the particles before
centrifugation in water vs ethyl alcohol. In ethyl
alcohol solution, the particles were more condensed
Fig. 1 Determination of the particle size after addition of different
quantities of GA. After addition of 200 mg into the mixture, we have
incubated the particles for 24 h. a The size of the particles, surface
area, is presented as microns. The significance in the groups for 50,
500, 2000 ll of added GA was equal to p = 1.62283E-27,
p = 0.001327 and p = 1.72321E-18, respectively. The difference
between the size of the large particle in the groups was
p = 0.000304246 and p = 0.003935424, for 50 ll GA vs 500 ll
and 50 vs 2000 ll, respectively. We have used Image Tool program
for the determination of particles sizes. b Representation of the
pictures for 500 ll and 50 vs 2000 ll GA containing groups
(respectively they are the pictures a0, b0 and c10 ? c20 ? c30
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than in water solution. Thus, for the better coupling
with the allopurinol, it was decided to use water
instead of alcohol (Fig. 3).
5. It was also determined the quantity of allopurinol in
20-mg albumin-containing samples.
We worked with DMSO vs water solutions of allop-
urinol with the concentration of 0.07 mg/ml. We have
added 200, 400, 800 and 2000 ll of allopurinol
solution for the incubation with the particles. Also,
we evaluated the effectiveness of the binding normal-
ized with the equal amount of allopurinol stock
solutions. For 200 ll of DMSO, the percentile of
bound allopurinol was equal to 110.04 ± 10.0, for
400—62.53 ± 1.25, for 800—31.26 ± 5.63 and for
2 ml—0.5 ± 0.75; for water solution of allopurinol:
for 200 ll—70.03 ± 40.02, 400—57.52 ± 11.26,
800—13.76 ± 0.63, 2 ml—6.0 ± 0.0 (Fig. 4).
p value in DMSO group was\0.05 (Kruskal–Wallis
one-way ANOVA on ranks).
6. Stability experiments (Fig. 5).
Particles were more stable until 15th h of incubation at
4 C in DMSO solution rather than in water. The volume
Fig. 2 Determination of the particle size after addition of different
quantities of albumin. A. The number of the particles was calculated
based on the micropictures and after utility of Pixcavator 6.0 program.
The significances between groups for 20, 200, 500 mg of added
albumin, reflected by p, were lower than 0.05 (one-way ANOVA).
b The size of the particles, surface area, is presented as the l2. The
significances between groups for 20, 200, 500 mg of added albumin,
reflected by p, were lower than 0.05 (one-way ANOVA). c Repre-
sentation of the pictures for 20, 200, 500 mg of albumin-containing
groups (respectively they are the pictures a0, b0 and c10 ? c20)
Fig. 3 Comparison of the particle shapes incubated in water vs
ethanol. In a is represented the picture of the particle in water solution
before centrifugation and, consequently, before formation of the
spherical shape of it, whereas on the b it is represented the picture of
the condensed in ethanol solution opened-shape particle
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of solution was also the defining factor for the stability
experiments (larger volume was correlating with visual-
ized less stability of the particles). The difference
between 2-h incubation in 200 ll of DMSO and 24 h
was statistically significant (2 ± 0; 39 ± 9; p\
0.044153); between 2 and 15 h for 400-ll volume in
DMSO was also different in statistically significant way
(1.5 ± 1,5 vs 11.2 ± 1.2; p\ 0.037052); between 2 and
24 h for 800 ll (12 ± 7.2 vs 14. ± 0.6, p\ 0.00226,
DMSO groups). Similar trend of dissolution of the
particles was noticed for water suspensions (Fig. 5).
Discussion
There are numerous publications describing the formation of
the albumin particles, which are very useful for the treatment
of cancer because of specific accumulation of the albumin
and because of its receptors existence in cancer tissue. The
experimental mixtures might contain albumin and
hypromellose acetate succinate [22], maleic anhydride
molecules, resulting in disk-shaped particles, and BSA with
N0,N0-dimethylacrylamide in water-in-oil and using ammo-
nium persulfate as an initiating agent [23], resulting in for-
mation of spheroid like 1–5 l particle [24]. We have used
GA as described in the study of Zhao D. [25]. In the first set
of the experiments, we were trying to evaluate the quantity
of GA which will be efficiently conjugating albumin and
will be forming the most useful shaped particles. After the
first set of the experiments, we concluded that 50 ll of GA is
the best quantity, which forms the smallest particles. During
the second set of the experiments, it was found that the
minimal quantity of the protein might force the formation of
the small-size particle, and the number or quantity of the
particles in these conditions was very high. Spheroid-type
particles were chosen due to their large total surface which
will be able to carry the highest concentration of the albu-
min. The allopurinol was not specifically conjugated with
the albumin particles to guarantee the free possible pene-
tration of the medicines in the capillaries after surface–sur-
face tight interaction of them with the endothelial cells to
provoke highly efficient penetration of allopurinol as the
medicine the treatment of ischemic stroke.
Also, we noticed that the binding of allopurinol with the
particles is much more effective, when DMSO and non-
water solutions are used. It might be suggested that the
higher effectiveness is based on abilities of allopurinol
solubility in water vs DMSO. Also, from Fig. 4 it is clear
that the binding process is much more effective in the
smaller volumes. This process is reflecting stability of the
particles in the solution. This means that in 24 h in aqueous
solution or in the blood, these particles might be dissolved,
which is the positive ability for these formulations and
evidences about spontaneous biodegradable ability with the
increase in albumin in plasma (Fig. 5). Increased plasma
albumin by itself might serve as a wonderful compound in
stroke treatment as the oncotic pressure-determining agent,
Fig. 4 Determination of bound with particle allopurinol quantity.
PerkinElmer Junior spectrophotometer was used to estimate the
quantity of the allopurinol in the samples. a Bound with the 20 mg of
the particles allopurinol. Allopurinol was added as a water solution or
as a dissolved in DMSO compound in the volumes equal to 200, 400,
800, 2000 ll (0.07 mg/ml). Controls point to the concentration of the
allopurinol as stock solutions of comparable with the samples
volumes. b Effectiveness (%) of allopurinol binding with the
particles. The concentration of the equal volume stocks solution of
the allopurinol was accounted as a 100 %
Fig. 5 Estimation of the particles stability over 24 h. Particles were
suspended in water as well as in DMSO of different volumes (200,
400 ll and 800 and 2 ml). Three time points were chosen 2 h, 15 and
24 h of incubation. The suspensions were centrifugated, and the in
supernatant the quantity of the proteins was assessed
Int Nano Lett (2016) 6:35–40 39
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preventing diffusion of the water from blood via disrupted
hematoencephalic barrier into the brain parenchyma.
In our studies, we have shown that inhibition of XO by its
classical inhibitor might initiate regenerative processes in
neuronal cell culture by the inhibition of purine catabolism by
feedback mechanism as well as by the inhibition of XO-
generated ROS [26–28]. On the other hand, we also propose
the utility of such albumin particles for the treatment of
stroke. Albumin is the compound, which might be useful in
the near future for the treatment of stroke [29] as an antihe-
morrhagic and anti-ischemic agent. It is in clinical trials [30].
A method for the generation 1- to 5-micron spheroid
particles has been adopted to assess the allopurinol quantity
in the coated particles, which might be useful in the future
for the treatment of ischemic stroke.
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